TRT and Kidney Function: What Research Says About Testosterone, CKD, and eGFR Monitoring

Testosterone and kidney health share a more complex relationship than most men realize. Chronic kidney disease affects roughly 15% of American adults, and men with CKD or reduced kidney function are significantly more likely to have low testosterone — some studies estimate hypogonadism rates of 40–50% in men with moderate to severe CKD. But does TRT make kidney problems worse, or could it potentially help? This article reviews what the current research shows and what kidney markers men on TRT should be monitoring.

Low Testosterone Is Common in Chronic Kidney Disease

Men with chronic kidney disease have a substantially higher prevalence of hypogonadism than the general population. The kidneys play a role in hormonal regulation, including the hypothalamic-pituitary-gonadal (HPG) axis. As kidney function declines, several mechanisms can reduce testosterone:

• Leydig cell dysfunction: Reduced responsiveness of testicular Leydig cells to luteinizing hormone (LH), meaning the testes produce less testosterone even when the pituitary signals for more.
• Elevated prolactin: Kidney failure can increase prolactin levels, which suppresses GnRH and downstream testosterone production.
• Chronic inflammation: Inflammatory cytokines (IL-6, TNF-alpha) are elevated in CKD and can suppress testicular steroidogenesis.
• Increased SHBG: Some CKD patients show elevated sex hormone-binding globulin, reducing free (bioavailable) testosterone even when total levels appear normal.

This means that men with kidney disease who are experiencing low energy, reduced muscle mass, or other hypogonadal symptoms should have their hormones assessed alongside their renal panel — the two conditions often interact.

What Recent Research Says About TRT and Kidney Safety

A growing body of evidence suggests that TRT does not worsen kidney function and may, in some populations, be associated with improved renal outcomes.

Diabetic Hypogonadal Men and Acute Kidney Injury

A 2025 retrospective cohort study published in Diabetes Care (PMC12487499) found that men with diabetes receiving testosterone therapy had a significantly lower risk of acute kidney injury (AKI) and a lower risk of kidney failure requiring renal replacement therapy compared to matched hypogonadal men who did not receive TRT. The study also found lower all-cause mortality in the TRT group, suggesting a systemic protective effect that extended to renal function.

TRT Safety in Established Chronic Kidney Disease

A safety analysis published in The World Journal of Men's Health (2025) evaluated testosterone therapy in men with pre-existing CKD. The study found that TRT did not worsen eGFR trajectories and was generally well-tolerated from a renal standpoint. The authors concluded that TRT is a "safe therapeutic option" in CKD patients, though they called for further prospective randomized controlled trials.

Long-Term Treatment and Renal Markers

A prospective controlled study published through Gavin Publishers reported improvements in both liver and kidney function markers among men receiving long-term testosterone treatment. The study linked these improvements to a reduced risk of myocardial infarction, stroke, and premature mortality in hypogonadal men. While this study is observational and requires replication, it contributes to a pattern suggesting that restoring physiologic testosterone may support overall metabolic and organ function.

Can TRT Improve Kidney Function?

It would be premature to claim that TRT improves kidney function directly. However, several plausible mechanisms could explain the associations seen in observational research:

• Improved body composition: Increased lean muscle mass and reduced visceral fat can improve insulin sensitivity, which is a known risk factor for CKD progression.
• Cardiovascular benefits: Adequate testosterone levels are associated with improved endothelial function and cardiovascular health, which directly supports renal perfusion.
• Reduced inflammation: TRT has been shown to reduce inflammatory markers (CRP, IL-6) in hypogonadal men, and chronic inflammation is a major driver of CKD progression.
• Better glycemic control: Several studies have linked TRT with improved insulin sensitivity and HbA1c in diabetic hypogonadal men, which indirectly protects kidney function.

None of these mechanisms amount to a proven treatment for kidney disease, and men with CKD should not start TRT solely with the goal of improving renal function. TRT is indicated for confirmed hypogonadism with clinical symptoms, and any kidney-related benefits would be secondary to restoring normal testosterone levels.

Key Kidney Markers to Monitor on TRT

If you are on TRT or considering it, your clinician should be tracking renal function as part of your baseline and follow-up labs. Here are the key markers:

eGFR (Estimated Glomerular Filtration Rate)

eGFR estimates how well your kidneys are filtering blood, calculated from serum creatinine, age, and sex. Normal eGFR is above 90 mL/min/1.73 m². An eGFR between 60–89 may indicate mild reduction, and values below 60 for three or more months meet the definition of CKD. Your baseline eGFR helps your doctor assess whether TRT is appropriate and at what monitoring cadence.

Serum Creatinine

Creatinine is a waste product from muscle metabolism. Because testosterone increases lean muscle mass, serum creatinine can rise modestly on TRT — this does not necessarily indicate kidney damage. The increase is expected with additional muscle mass and should be interpreted alongside eGFR trends rather than in isolation. A creatinine rise of 0.1–0.3 mg/dL with stable eGFR can be a normal physiologic response.

BUN (Blood Urea Nitrogen)

BUN measures urea nitrogen in your blood, a marker of protein metabolism and kidney clearance. Elevated BUN can suggest reduced kidney function, dehydration, or high protein intake. Your clinician will usually interpret BUN alongside creatinine and eGFR.

Urinalysis and Albumin-to-Creatinine Ratio (ACR)

Protein in the urine (proteinuria or albuminuria) is an early indicator of kidney damage. An ACR above 30 mg/g is considered abnormal and warrants follow-up. If you have baseline proteinuria, your clinician may want to repeat this test after starting TRT to ensure no worsening.

Contraindications and Special Considerations

TRT is not contraindicated solely by the presence of CKD, but clinicians exercise additional caution in several scenarios:

• End-stage renal disease (ESRD): Men on dialysis have complex hormonal profiles, and the risks/benefits of TRT should be evaluated case by case with a nephrologist.
• Severe uncontrolled hypertension: TRT can increase blood pressure in some men, and uncontrolled hypertension accelerates kidney damage.
• Active prostate or breast cancer: Absolute contraindications to TRT regardless of kidney status.
• Polycythemia: TRT increases red blood cell production, and CKD patients may already have anemia (reduced red blood cells). Your hematocrit must be monitored.

Monitoring Cadence for Men with Kidney Concerns

For men with normal kidney function, a standard TRT monitoring schedule includes labs at baseline, 3 months, 6 months, and annually. If you have CKD (Stage 2 or higher) or baseline kidney concerns, your clinician may adjust this to:

• Baseline: Total testosterone, free testosterone, LH, FSH, SHBG, estradiol, CBC, CMP (includes creatinine, BUN, eGFR calculation), PSA, and urinalysis with ACR.
• 3 months: Testosterone, CBC, CMP, and urinalysis to confirm stability.
• 6 months: Full panel repeat including renal markers.
• Annually: Ongoing monitoring, with renal function tracked at each visit if eGFR is below 60.

The key is trend data — a single elevated creatinine means less than a sustained decline in eGFR over time.

Practical Takeaways

• Low testosterone is common in men with chronic kidney disease, often affecting 40–50% of patients.
• Current evidence (2024–2025) does not show that TRT worsens kidney function and suggests possible protective effects in diabetic hypogonadal populations.
• Serum creatinine can rise on TRT due to increased muscle mass — this is not necessarily a sign of kidney damage and should be interpreted alongside eGFR.
• Kidney function (eGFR, creatinine, BUN, urinalysis) should be part of your baseline and follow-up TRT labs.
• Men with CKD or kidney concerns should discuss TRT with both their prescribing clinician and nephrologist.
• TRT is not a treatment for kidney disease — it is a treatment for confirmed hypogonadism that may have secondary benefits for overall metabolic health.

Frequently Asked Questions

Does testosterone damage your kidneys?

Current evidence does not support the claim that TRT causes kidney damage. In fact, recent studies suggest that restoring normal testosterone levels in hypogonadal men may be associated with a lower risk of acute kidney injury and kidney failure, particularly in diabetic populations.

Why does my creatinine go up on TRT?

Creatinine is produced by muscle tissue. Since testosterone increases lean muscle mass, a modest rise in serum creatinine is expected. This does not indicate kidney damage. Your doctor should interpret creatinine alongside eGFR — if eGFR remains stable, the creatinine rise is likely just a reflection of additional muscle.

Can I take TRT if I have chronic kidney disease?

In many cases, yes. Research published in 2025 suggests TRT is safe in CKD patients from a renal standpoint. However, the decision should be individualized, weighing your testosterone levels, symptoms, stage of CKD, and other health factors. Coordination between your prescribing clinician and nephrologist is recommended.

Does TRT help with kidney function?

TRT is not indicated as a treatment for kidney disease. However, some observational studies have found associations between testosterone therapy and improved renal markers in hypogonadal men, possibly through mechanisms like reduced inflammation, better glycemic control, and improved body composition. These are secondary effects, not direct renal treatment.

How often should kidney function be checked on TRT?

If you have normal kidney function, annual monitoring of creatinine, BUN, and eGFR is typically sufficient. If you have pre-existing CKD or baseline renal concerns, your clinician may check these markers every 3–6 months to establish stable trends early in treatment.